CCR1 and cancer: Those compounds were colistimethate sodium, a broad-spectrum antibiotic [20]; flubendazole, which has been repurposed to inhibit cancer cell growth [21]; and BX471, a CCR1 antagonist, which has shown promise in modulating proinflammatory and autoimmune diseases [22].